AUSVAXSAFETY summary report 2020: 12 month infographic

Twelve month schedule point.


AUSVAXSAFETY summary report 2020: 12 month infographic

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
General public

11,575 parents/carers responded to an SMS about their child’s health a few days after their 12-month vaccinations. 89% reported no adverse events. 11% reported any adverse event, including 1.1% who reported taking their child to a doctor or emergency department in the days after vaccination. The adverse events they reported were similar to the types of adverse events reported overall. 1,247 parents/carers reported one or more adverse events. The most commonly reported were fever (449 reports), irritability (446 reports), injection site swelling or redness (353 reports), sleep pattern change (288 reports) and tiredness (286 reports). These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination. Aboriginal and Torres Strait Islander children who received these vaccines had the same rates and types of adverse events as other children. Vaccines given at 12 months in 2020 are Priorix or M-M-R II (protects against measles, mumps, rubella), Nimenrix (protects against meningococcal disease types A, C, W and Y) and Prevenar 13 (protects against pneumococcal disease).

Part of a collection:

Help us improve

If you would like a response please use the enquiries form instead.